Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amazon.com said on Tuesday its online pharmacy will automatically apply manufacturer-sponsored coupons to more than 15 insulin and diabetes medicines to help patients access discounts pledged by the... -Today at 07:00 am- MarketScreener
New data on the heart benefit of an obesity drug from Novo Nordisk increases the chances of a pay-off for it and rival Eli Lilly, which have spent a record amount on U.S. lobbying to win government backing for the drugs, analysts and experts said. U.S. law classifies weight-loss treatments as lifestyle drugs and bars Medicare from paying for them. Novo and Eli Lilly have spent nearly $1.3 million this year lobbying the U.S. Congress on obesity and specifically on a bill reintroduced in July that would allow the Medicare health plan to reimburse these medicines.
Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment.
By Maggie Fick and Nikolaj Skydsgaard COPENHAGEN/LONDON (Reuters) -Wegovy maker Novo Nordisk said on Tuesday a large study had shown the highly effective
COPENHAGEN/LONDON (Reuters) -Novo Nordisk said on Tuesday a large study had shown its highly effective obesity drug Wegovy also had a clear cardiovascular benefit, boosting the Danish drugmaker's hopes of moving beyond Wegovy's image as a lifestyle drug. The late-stage trial showed that patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo, Novo said. The study, called SELECT, involved 17,500 overweight or obese people with a history of heart disease aged 45 years or older with no prior history of diabetes.